Titre :
|
Cervical Screening and Cervical Cancer Death Among Older Women : A Population-Based, Case-Control Study (2014)
|
Auteurs :
|
Alison-S RUSTAGI ;
Aruna KAMINENI ;
Department of Epidemiology, University of Washington (Seattle WA, Etats-Unis) ;
Sheila WEINMANN ;
Cancer Epidemiology Research Cooperative, Fred Hutchinson Cancer Research Center (Seattle WA, Etats-Unis) ;
Susan-D REED ;
Polly NEWCOMB ;
Noel-S Weiss
|
Type de document :
|
Article
|
Dans :
|
American journal of epidemiology (vol. 179, n° 9, mai 2014)
|
Pagination :
|
1107-1114
|
Langues:
|
Anglais
|
Mots-clés :
|
Dépistage
;
Mort
;
Mortalité
;
Personne âgée
;
Femme
;
Population
;
Enquête cas témoin
;
Epidémiologie
;
Frottis
;
Utérus
;
Homme
;
Cancer
|
Résumé :
|
[BDSP. Notice produite par INIST-CNRS kqDmR0xA. Diffusion soumise à autorisation]. Recent research suggests that cervical screening of older women is associated with a considerable decrease in cervical cancer incidence. We sought to quantify the efficacy of cervical cytology screening to reduce death from this disease. Among enrollees of 2 US health plans, we compared Papanicolaou smear screening histories of women aged 55-79 years who died of cervical cancer during 1980-2010 (cases) to those of women at risk of cervical cancer (controls). Controls were matched 2 : 1 to cases on health plan, age, and enrollment duration. Cytology screening during the detectable preclinical phase, estimated as the 5-7 years before diagnosis during which cervical neoplasia is asymptomatic but cytologically detectable, was ascertained from medical records. A total of 39 cases and 80 controls were eligible. The odds ratio of cervical cancer death associated with screening during the presumed detectable preclinical phase was 0.26 (95% confidence interval : 0.10,0.63) after adjustment for matching characteristics, smoking, marital status, and race/ethnicity using logistic regression. We estimate that cervical cytology screening of all women aged 55-79 years in the United States could avert 630 deaths annually. These results provide a minimum estimate of the efficacy of human papillomavirus DNA screening-a more sensitive test-to reduce cervical cancer death among older women.
|